Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.48 |
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2583703 | 0.80 | CA12 (0.48) | CA12CA14CA2GAAALDH1A1 | |
| SCHEMBL22475391 | 0.78 | CA12 (0.47) | CA12CA14CA2GAAALDH1A1 | |
| SCHEMBL7840740 | 0.78 | CA12 (0.52) | CA12CA14CA2GAAALDH1A1 | |
| SCHEMBL15592453 | 0.78 | CA12 (0.47) | CA12CA14CA2GAAALDH1A1 | |
| SCHEMBL4674334 | 0.78 | CA12 (0.47) | CA12CA14CA2GAAALDH1A1 | |
| SCHEMBL16918055 | 0.78 | LMNA (0.38) | CA12CA14CA2GAAALDH1A1 | |
| SCHEMBL28326823 | 0.78 | CA12 (0.51) | CA12CA14CA2GAAALDH1A1 | |
| SCHEMBL20335051 | 0.76 | CA12 (0.72) | CA12CA14CA2GAAALDH1A1 | |
| SCHEMBL3250232 | 0.76 | ALDH1A1 (0.32) | CA12CA14CA2GAAALDH1A1 | |
| SCHEMBL25039078 | 0.75 | CA12 (0.53) | CA12CA14CA2GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111116572-B | Oxadiazole derivative, preparation method and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-10888554-B2 | Salts of heterocyclic modulators of HIF activity for treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-01-12 | — | — | US | disclosed |
| US-20200171017-A1 | SALTS OF HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-06-04 | — | — | US | disclosed |
| CN-111116572-A | Oxadiazole derivatives, their preparation and use | 石药集团中奇制药技术（石家庄）有限公司 | 2020-05-08 | — | — | CN | disclosed |
| EP-2888255-B1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | UNIV TEXAS (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20170275317-A1 | COMPLEXES AND METHODS FOR THEIR PREPARATION | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-09-28 | — | — | US | disclosed |
| US-20170216271-A1 | SALTS OF HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-08-03 | — | — | US | disclosed |
| US-9663504-B2 | Salts of heterocyclic modulators of HIF activity for treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-05-30 | — | — | US | disclosed |
| US-20170121342-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM | 2017-05-04 | — | — | US | disclosed |
| US-9481692-B2 | Heterocyclic modulators of HIF activity for treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-11-01 | — | — | US | disclosed |
| US-20140073634-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140066424-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140057914-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2014031936-A2 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | JONES PHILIP (US) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014031933-A2 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | JONES PHILIP (US) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014031928-A2 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | JONES PHILIP (US) | 2014-02-27 | — | — | WO | disclosed |
| US-7812016-B2 | Naphthyridine integrase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2010-10-12 | — | — | US | disclosed |
| US-20070142365-A1 | Naphthyridine integrase inhibitors | GSK LLC | 2007-06-21 | — | — | US | disclosed |
| CN-1273585-A | Substituted 3- (1, 2-benzisothiazole or isoxazol-5-yl) -substituted pyrimidines as herbicides | AMERICAN CYANAMID CO (US) | 2000-11-15 | — | — | CN | disclosed |
| WO-1997031902-A1 | QUINOXALINE DERIVATIVES USEFUL IN THERAPY | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200171017-A1 | SALTS OF HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, VHL, HIF1A | CA12 715/4885CA14 944/4885CA2 87/4885 |
| US-20070142365-A1 | Naphthyridine integrase inhibitors | PCNA, SAMHD1, NTPCR | CA12 4881/4885CA14 4877/4885CA2 4848/4885 |
| US-20170275317-A1 | COMPLEXES AND METHODS FOR THEIR PREPARATION | CYCS, COX6C, SOD1 | CA12 810/4885CA14 745/4885CA2 2997/4885 |
| US-20170216271-A1 | SALTS OF HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, VHL, HIF1A | CA12 715/4885CA14 944/4885CA2 87/4885 |
| US-20140057914-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, HIF1A, EGLN3 | CA12 1577/4885CA14 1855/4885CA2 467/4885 |
| US-20140066424-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, HIF1A, EGLN3 | CA12 1577/4885CA14 1855/4885CA2 467/4885 |
| US-10888554-B2 | Salts of heterocyclic modulators of HIF activity for treatment of disease | HIF1AN, VHL, HIF1A | CA12 715/4885CA14 944/4885CA2 87/4885 |
| US-20140073634-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, HIF1A, EGLN3 | CA12 1577/4885CA14 1855/4885CA2 467/4885 |
| US-20170121342-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, HIF1A, EGLN3 | CA12 1577/4885CA14 1855/4885CA2 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.